PSTV

Plus Therapeutics Inc

Add to Watchlist

Advanced Chart

0.530

-0.067(-11.232%)1D

Overview
Forecast
Valuation
Earnings

Line

Candle

YTD

High

0.589

Open

0.5889

VWAP

0.55

Vol

13.60M

Mkt Cap

32.05M

Low

0.5202

Amount

7.50M

EV/EBITDA(TTM)

Total Shares

5.70M

22.18M

EV/OCF(TTM)

P/S(TTM)

0.94

Plus Therapeutics, Inc. is a clinical-stage pharmaceutical company. The Company is engaged in developing targeted radiotherapeutics for difficult-to-treat cancers of the central nervous system. Combining image-guided local beta radiation and targeted drug delivery approaches, it is advancing a pipeline of product candidates with lead programs in leptomeningeal metastases (LM) and recurrent glioblastoma (GBM). Its lead radiotherapeutic candidate, REYOBIQ (rhenium (186Re) obisbemeda), is designed specifically for CNS cancers including GBM, LM, and pediatric brain cancers (PBC) by direct localized delivery utilizing approved standard-of-care tissue access such as with convection-enhanced delivery (CED) and intraventricular brain (Ommaya reservoir) catheters. Its radiotherapeutic candidate, Rhenium-188 NanoLiposome Biodegradable Alginate Microsphere (188RNL-BAM), is designed to treat many solid organ cancers including primary and secondary liver cancers via intra-arterial injections.

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q2

FY2025Q3

FY2025Q4

1.49M

+16.21%

-0.130

-71.11%

1.83M

+25.46%

-0.130

-64.86%

1.80M

+27.17%

-0.140

-71.43%

Estimates Revision

The market is revising Upward the revenue expectations for Plus Therapeutics, Inc. (PSTV) for FY2025, with the revenue forecasts being adjusted by 27.13% over the past three months. During the same period, the stock price has changed by -37.23%.

Revenue Estimates for FY2025

Revise Upward

+27.13%

In Past 3 Month

EPS Estimates for FY2025

Revise Upward

+27.66%

In Past 3 Month

Stock Price

Go Down

-37.23%

In Past 3 Month

3 Analyst Rating

2117.82% Upside

Wall Street analysts forecast PSTV stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for PSTV is 11.75 USD with a low forecast of 3.00 USD and a high forecast of 20.50 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

2 Buy

1 Hold

0 Sell

Moderate Buy

2117.82% Upside

Current: 0.530

Low

3.00

Averages

11.75

High

20.50

2117.82% Upside

Current: 0.530

Low

3.00

Averages

11.75

High

20.50

H.C. Wainwright

Sean Lee

Buy

downgrade

2025-06-27

Reason

H.C. Wainwright

Sean Lee

Price Target

2025-06-27

downgrade

Buy

Reason

H.C. Wainwright analyst Sean Lee lowered the firm's price target on Plus Therapeutics to $3 from $5.50 and keeps a Buy rating on the shares. The firm cites the restructured number of outstanding shares and warrants associated with the March equity offering for the target cut.

Ascendiant Capital

Edward Woo

Strong Buy

Maintains

$19 → $20

2025-04-21

Reason

Ascendiant Capital

Edward Woo

Price Target

$19 → $20

2025-04-21

Maintains

Strong Buy

Reason

D. Boral Capital

Jason Kolbert

Strong Buy

Maintains

2025-03-28

Reason

D. Boral Capital

Jason Kolbert

Price Target

2025-03-28

Maintains

Strong Buy

Reason

HC Wainwright & Co.

Sean Lee

Strong Buy

Maintains

$8 → $5.5

2025-03-28

Reason

HC Wainwright & Co.

Sean Lee

Price Target

$8 → $5.5

2025-03-28

Maintains

Strong Buy

Reason

D. Boral Capital

Jason Kolbert

Strong Buy

Maintains

2025-03-21

Reason

D. Boral Capital

Jason Kolbert

Price Target

2025-03-21

Maintains

Strong Buy

Reason

D. Boral Capital initiated coverage of Plus Therapeutics with a Buy rating and $9 price target. Plus is advancing a unique approach in cancer treatment through its proprietary combination of a powerful diagnostic coupled with a therapeutic radiopharmaceuticals, says the analyst. The company's lead asset, Rhenium-186, is a radionuclide that holds promise for treating cancers of the central nervous system, particularly Leptomeningeal Metastases and recurrent glioblastoma, the analyst tells investors.

D. Boral Capital

Jason Kolbert

Strong Buy

Initiates

2025-03-17

Reason

D. Boral Capital

Jason Kolbert

Price Target

2025-03-17

Initiates

Strong Buy

Reason

See All Ratings

Valuation Metrics

The current forward P/E ratio for Plus Therapeutics Inc (PSTV.O) is -1.08, compared to its 5-year average forward P/E of -1.99. For a more detailed relative valuation and DCF analysis to assess Plus Therapeutics Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-1.99

Current PE

-1.08

Overvalued PE

2.80

Undervalued PE

-6.77

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

-0.72

Current EV/EBITDA

-1.59

Overvalued EV/EBITDA

0.14

Undervalued EV/EBITDA

-1.58

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A

5Y Average PS

2.47

Current PS

4.54

Overvalued PS

8.71

Undervalued PS

-3.76

Financials

Annual

Quarterly

FY2025Q1

YoY :

-36.85%

1.06M

Total Revenue

FY2025Q1

YoY :

+7.18%

-3.54M

Operating Profit

FY2025Q1

YoY :

+433.61%

-17.40M

Net Income after Tax

FY2025Q1

YoY :

+58.67%

-1.19

EPS - Diluted

FY2025Q1

YoY :

+35.62%

-6.18M

Free Cash Flow

FY2025Q1

YoY :

0.00%

100.00

Gross Profit Margin - %

FY2025Q1

YoY :

+745.02%

-1.64K

Net Margin - %

Trading Trends

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

0-3

Months

0.0

USD

3-6

Months

0.0

USD

6-9

Months

0.0

USD

0-12

Months

0.0

USD

Bought

0-3

0.0

USD

Months

3-6

0.0

USD

Months

6-9

0.0

USD

Months

0-12

53.1K

USD

Months

Hedge Fund

Hedge Funds are Neutral. There are no significant trading trends over the last quarter.

Sold

0-3

Months

0.0

Volume

3-6

Months

0.0

Volume

6-9

Months

0.0

Volume

0-12

Months

0.0

Volume

Bought

0-3

0.0

Volume

Months

3-6

0.0

Volume

Months

6-9

0.0

Volume

Months

0-12

0.0

Volume

Months

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

0-3

Months

0.0

USD

3-6

Months

0.0

USD

6-9

Months

0.0

USD

0-12

Months

0.0

USD

Bought

0-3

0.0

USD

Months

3-6

0.0

USD

Months

6-9

0.0

USD

Months

0-12

0.0

USD

Months

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

0-3

Months

0.0

USD

3-6

Months

0.0

USD

6-9

Months

0.0

USD

0-12

Months

0.0

USD

Bought

0-3

0.0

USD

Months

3-6

0.0

USD

Months

6-9

0.0

USD

Months

0-12

53.1K

USD

Months

PSTV News & Events

Events Timeline

2025-07-23 (ET)

2025-07-23

07:35:53

Plus Therapeutics announces $1.6M advance payment from CPRIT

2025-07-08 (ET)

2025-07-08

07:33:43

Plus Therapeutics announces initial patients treated in ReSPECT-LM trial

2025-06-30 (ET)

2025-06-30

07:33:02

Plus Therapeutics reaches FDA agreement to initiate ReSPECT-LM trial

News

9.0

07-15Newsfilter

Plus Therapeutics Presents ReSPECT-LM Clinical Trial Results for REYOBIQ™ in Patients with Leptomeningeal Metastases

9.0

07-08Newsfilter

Plus Therapeutics Announces Initial Patients Successfully Treated in ReSPECT-LM Dose Optimization Trial for REYOBIQ™ in Leptomeningeal Metastases

9.0

06-30Newsfilter

Plus Therapeutics Announces FDA Agreement to Initiate ReSPECT-LM Dose Optimization Trial for REYOBIQ™ in Leptomeningeal Metastases

People Also Watch

VIRX

Viracta Therapeutics Inc

Arcadia Biosciences Inc

BioNexus Gene Lab Corp

Airnet Technology Inc

1.391

USD

+1.90%

FAQ

What is Plus Therapeutics Inc (PSTV) stock price today?

The current price of PSTV is 0.5298 USD — it has decreased -11.23 % in the last trading day.

PSTV

Market Estimates

Valuation Metrics

Forward PE

Forward EV/EBITDA

Forward PS

Financials

Trading Trends

PSTV News & Events

Events Timeline

News

People Also Watch

FAQ

What is Plus Therapeutics Inc (PSTV) stock price today?

What is Plus Therapeutics Inc (PSTV)'s business?

What is the price predicton of PSTV Stock?

What is Plus Therapeutics Inc (PSTV)'s revenue for the last quarter?

What is Plus Therapeutics Inc (PSTV)'s earnings per share (EPS) for the last quarter?

What changes have occurred in the market's expectations for Plus Therapeutics Inc (PSTV)'s fundamentals?

How many employees does Plus Therapeutics Inc (PSTV). have?

What is Plus Therapeutics Inc (PSTV) market cap?